Article

CustomVue offers good results in mixed astigmatism

Excellent visual outcomes can be achieved in subjects with mixed astigmatism when using the VISX wavefront platform's CustomVue iris registration system (AMO).

Excellent visual outcomes can be achieved in subjects with mixed astigmatism when using the VISX wavefront platform's CustomVue iris registration system (AMO), according to Baha Toygar and co-workers from the Dunya Eye Hospital, Istanbul, Turkey.

Sixteen eyes with mixed astigmatism were enrolled into the prospective study in which all LASIK procedures were performed by the same surgeon.

Three months following surgery, mean astigmatism had reduced from -3.14±1.06 D to -0.33±0.44 D. The majority of eyes (81%) had less than -0.50 D residual astigmatism and 87.5% had less than -1.0 D. Mean uncorrected and best corrected visual acuity (UCVA & BCVA) improved from 0.24±0.13 to 0.79±0.27 and from 0.84±0.20 to 0.95±0.11, respectively.

Overall, these results demonstrate that the VISX wavefront platform's CustomVue iris registration system can offer excellent visual outcomes for subjects with mixed astigmatism.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.